Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT01789983
Official study title

Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy

Study summary

The study will look at conducting a medium-intense walking program called Walk With Ease with cancer patients age 60 and above who are starting chemotherapy treatment. We will measure how many of these patients complete their participation in this program.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedWalk With Ease Program and Collect Blood, GA and Other Survey Tools

The study team can explain what participation involves.

Who it may be forBreast Cancer · Colon Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 20, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?UNC Lineberger Comprehensive Cancer Center

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
UNC Lineberger Comprehensive Cancer Center
Interventions being studied
Behavioral: Walk With Ease Program; Other: Collect Blood, GA and Other Survey Tools
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Chemotherapy→Supportive or behavioral care→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • ≥60 years of age, male or female
  • Histologically confirmed Stage I, II or III breast cancer (if the patient has had more than one breast cancer diagnosis, then the most recent diagnosis); Stage I, II or III lung cancer, or Stage II or III colon cancer
  • Scheduled to begin a chemotherapy (or concomitant chemoradiotherapy) regimen that will last at least 6 weeks in duration
  • English speaking
  • IRB approved, signed written informed consent
  • Approval from their treating physician to engage in moderate-intensity physical activity
  • Patient-assessed ability to walk and engage in moderate physical activity
  • Willing and able to meet all study requirements.
Reasons someone may not be able to joinExclusion criteria
  • One or more significant medical conditions that in the physician's judgment preclude participation in the walking intervention
  • Cancer surgery scheduled within the study period
  • Unable to walk or engage in moderate-intensity physical activity

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of North Carolina Cancer HospitalChapel Hill, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 20, 2024. Always confirm current availability with the study team.

View original record ↗